We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should Investors Buy Align as Growth Meets Valuation and Demand Risks?
Read MoreHide Full Article
Key Takeaways
Align's Clear Aligner shipments rose 7.4% to a record 691,800 cases, led by strong international growth.
ALGN faces weak dental equipment demand and a shift toward lower-priced scanners, leases and rentals.
Align's valuation discount offers support, but negative EPS growth and lower estimates favor patience.
Align Technology (ALGN - Free Report) presents a split investment case. Clear Aligner volumes, international adoption and cash generation are improving, giving the company several durable growth levers.
The offset is near-term pressure from softer North American retail demand, weak dental capital-equipment spending and a lower-priced scanner mix. That makes the stock’s valuation discount relevant, but not enough by itself to support a more aggressive stance.
Align’s International Growth Supports the Bull Case
Second-quarter 2026 Clear Aligner shipments reached a record 691,800 cases, up 7.4% year over year. EMEA and APAC both delivered double-digit volume growth, while Latin America posted record second-quarter shipments.
Doctor participation also broadened, with a record 89,200 doctors submitting Invisalign cases and utilization rising 3.8%. Management now expects 2026 Clear Aligner volume growth of approximately 6%, above its prior mid-single-digit view.
Based on short-term price targets offered by 14 analysts, the average price target for Align Technology comes to $208.50. The average price target represents an increase of 19.81% from the last closing price.
Image Source: Zacks Investment Research
ALGN’s Broader Portfolio Expands Its Opportunity
Align is extending Invisalign beyond traditional adult and teen alignment through Invisalign First, the Invisalign Palatal Expander and mandibular advancement products. These offerings target growing patients and more complex cases.
Teen and growing-patient treatment starts increased 7.2% to 240,000 cases in the second quarter. Broader launches across EMEA and APAC, including newer approvals and commercial rollouts, could widen adoption across patient groups and geographies.
Align’s Digital Platform Adds Longer-Term Leverage
Scanner placements to new doctors reached a record level and increased at a double-digit rate, while the active installed base grew about 11%. More than 12.4 million restorative, wellness and orthodontic scans were completed in the quarter, up 16%.
Exocad revenues also grew at a double-digit rate. A larger scanner base can deepen integration between diagnostics, treatment planning, restorative workflows and Clear Aligner conversion, creating longer-term leverage even when upfront hardware revenue is pressured.
ALGN Faces Demand and Scanner Pricing Pressure
Systems and Services revenues declined 10.8% year over year to $185.3 million as capital-equipment demand stayed weak and customers shifted toward lower-priced scanners, leases, rentals and certified pre-owned systems. Management expects 2026 segment revenues to decline 6%-8% even as scanner shipments rise at a double-digit rate.
Competition adds another constraint. Dentsply Sirona Inc. (XRAY - Free Report) participates across orthodontics, CAD/CAM and dental equipment, while Envista Holdings Corporation (NVST - Free Report) offers clear aligners through its Ormco business. Their broad dental portfolios reinforce the need for Align to sustain doctor adoption and product differentiation.
Align’s Valuation Offers Support but Not a Clean Signal
ALGN trades at 14.6X forward 12-month earnings, below 17.8X for its Zacks sub-industry and its five-year median of 28.4X. The discount provides valuation support after a period of uneven demand.
Image Source: Zacks Investment Research
Yet the current fiscal year EPS growth projection is negative 18.3%. The EPS estimate has also moved 1.1% lower over the past four weeks, showing why a low multiple does not automatically translate into an attractive entry point.
ALGN’s Mixed Scores Support a Measured Stance
The balance of improving Clear Aligner demand, international expansion and digital-platform adoption against scanner pricing pressure and softer retail demand favors patience rather than an outright buy case. Valuation is more supportive, but earnings trends remain a restraint.
Align currently carries a Zacks Rank #3 (Hold), with a VGM Score of B, Value Score of B, Growth Score of B and Momentum Score of F. The favorable Value and Growth scores recognize useful attributes, but the weak Momentum Score and Hold rank fit a selective posture while investors wait for firmer earnings and demand signals.
View the Zacks #1 Rank List
Image: Bigstock
Should Investors Buy Align as Growth Meets Valuation and Demand Risks?
Key Takeaways
Align Technology (ALGN - Free Report) presents a split investment case. Clear Aligner volumes, international adoption and cash generation are improving, giving the company several durable growth levers.
The offset is near-term pressure from softer North American retail demand, weak dental capital-equipment spending and a lower-priced scanner mix. That makes the stock’s valuation discount relevant, but not enough by itself to support a more aggressive stance.
Align’s International Growth Supports the Bull Case
Second-quarter 2026 Clear Aligner shipments reached a record 691,800 cases, up 7.4% year over year. EMEA and APAC both delivered double-digit volume growth, while Latin America posted record second-quarter shipments.
Doctor participation also broadened, with a record 89,200 doctors submitting Invisalign cases and utilization rising 3.8%. Management now expects 2026 Clear Aligner volume growth of approximately 6%, above its prior mid-single-digit view.
Based on short-term price targets offered by 14 analysts, the average price target for Align Technology comes to $208.50. The average price target represents an increase of 19.81% from the last closing price.
Image Source: Zacks Investment Research
ALGN’s Broader Portfolio Expands Its Opportunity
Align is extending Invisalign beyond traditional adult and teen alignment through Invisalign First, the Invisalign Palatal Expander and mandibular advancement products. These offerings target growing patients and more complex cases.
Teen and growing-patient treatment starts increased 7.2% to 240,000 cases in the second quarter. Broader launches across EMEA and APAC, including newer approvals and commercial rollouts, could widen adoption across patient groups and geographies.
Align’s Digital Platform Adds Longer-Term Leverage
Scanner placements to new doctors reached a record level and increased at a double-digit rate, while the active installed base grew about 11%. More than 12.4 million restorative, wellness and orthodontic scans were completed in the quarter, up 16%.
Exocad revenues also grew at a double-digit rate. A larger scanner base can deepen integration between diagnostics, treatment planning, restorative workflows and Clear Aligner conversion, creating longer-term leverage even when upfront hardware revenue is pressured.
ALGN Faces Demand and Scanner Pricing Pressure
Systems and Services revenues declined 10.8% year over year to $185.3 million as capital-equipment demand stayed weak and customers shifted toward lower-priced scanners, leases, rentals and certified pre-owned systems. Management expects 2026 segment revenues to decline 6%-8% even as scanner shipments rise at a double-digit rate.
Competition adds another constraint. Dentsply Sirona Inc. (XRAY - Free Report) participates across orthodontics, CAD/CAM and dental equipment, while Envista Holdings Corporation (NVST - Free Report) offers clear aligners through its Ormco business. Their broad dental portfolios reinforce the need for Align to sustain doctor adoption and product differentiation.
Align’s Valuation Offers Support but Not a Clean Signal
ALGN trades at 14.6X forward 12-month earnings, below 17.8X for its Zacks sub-industry and its five-year median of 28.4X. The discount provides valuation support after a period of uneven demand.
Image Source: Zacks Investment Research
Yet the current fiscal year EPS growth projection is negative 18.3%. The EPS estimate has also moved 1.1% lower over the past four weeks, showing why a low multiple does not automatically translate into an attractive entry point.
ALGN’s Mixed Scores Support a Measured Stance
The balance of improving Clear Aligner demand, international expansion and digital-platform adoption against scanner pricing pressure and softer retail demand favors patience rather than an outright buy case. Valuation is more supportive, but earnings trends remain a restraint.
Align currently carries a Zacks Rank #3 (Hold), with a VGM Score of B, Value Score of B, Growth Score of B and Momentum Score of F. The favorable Value and Growth scores recognize useful attributes, but the weak Momentum Score and Hold rank fit a selective posture while investors wait for firmer earnings and demand signals.